U.S. Markets open in 6 hrs 30 mins

InSite Vision completes DOUBle Phase 3 study of AzaSite Plus, DexaSite

InSite Vision announced that the last patient has completed dosing and evaluation in the DOUBle Phase 3 clinical trial of AzaSite Plus and DexaSite for the treatment of blepharitis. The DOUBle study enrolled more than 900 patients with moderate-to-severe blepharitis in a four-arm trial designed to evaluate the efficacy and safety of both product candidates simultaneously. InSite Vision expects that top-line data from the DOUBle Phase 3 clinical trial will be available in the second quarter of 2013.